<DOC>
	<DOCNO>NCT01841762</DOCNO>
	<brief_summary>SYMPHONY prospective , multi-center , open-label , single-arm , Phase 3b psychometric validation study PAH-SYMPACT , new quality life questionnaire patient pulmonary arterial hypertension . Patients study 5 1/2 month , 4 month receive macitentan , 10 mg , daily . The primary objective demonstrate final content validity PAH SYMPACT instrument , demonstrate psychometric characteristic reliability construct validity PAH-SYMPACT instrument , demonstrate ability PAH SYMPACT instrument detect change . The secondary objective ass safety macitentan patient pulmonary arterial hypertension . The exploratory objective explore effect macitentan PAH symptom impact ( measure PAH-SYMPACT ) patient pulmonary arterial hypertension .</brief_summary>
	<brief_title>Clinical Study Macitentan Patients With Pulmonary Arterial Hypertension Psychometrically Validate PAH-SYMPACT Instrument</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>1 . Signed informed consent prior initiation study mandate procedure 2 . Patients symptomatic PAH World Health Organization ( WHO ) Functional Class ( FC ) II IV 3 . Patients PAH belong one follow subgroup Dana Point Clinical Classification Group 1 : 1 . Idiopathic , 2 . Heritable , 3 . Drug toxin induce , 4 . Associated one following : i. Connective tissue disease ii . Congenital heart disease simple systemictopulmonary shunt least one year surgical repair iii . HIV infection 4 . Documented hemodynamic diagnosis PAH right heart catheterization perform time prior Screening showing : 1 . Resting mean pulmonary arterial pressure ( mPAP ) ≥ 25 mmHg 2 . Resting pulmonary vascular resistance ( PVR ) &gt; 240 dyn•s•cm5 3 . Pulmonary capillary wedge pressure ( PCWP ) leave ventricular end diastolic pressure ( LVEDP ) ≤ 15 mmHg 5 . 6minute walk distance ( 6MWD ) ≥ 150 Screening 6 . Able fluently speak read English 7 . For patient phosphodiesterase type5 inhibitor ( PDE5i ) , inhaled prostacyclin analogue , calcium channel blocker , stable dos least 3 month prior Visit 2 8 . For patient oral diuretic , stable dos least 4 week prior Visit 2 9 . Men woman age 18 old 1 . A woman consider childbearing potential unless : Has yet enter puberty , Does uterus , Has go menopause ( period least 12 month natural reason , ovary remove ) 2 . A woman childbearing potential eligible meet criterion : Has negative serum pregnancy test Screening negative urine pregnancy test Baseline agree perform monthly urine pregnancy test , Agrees use two method contraception ( one method patient progesterone implant intrauterine device tubal sterilization ) Screening Visit 1 one month study drug discontinuation 1 . Moderate severe obstructive lung disease : forced expiratory volume one second ( FEV1 ) / force vital capacity &lt; 70 % FEV1 &lt; 65 % predict value bronchodilator administration 2 . Moderate severe restrictive lung disease : total lung capacity &lt; 60 % predict value 3 . Hemoglobin &lt; 75 % low limit normal range screen 4 . Serum aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3 time upper limit normal ( ULN ) screen 5 . Estimated creatinine clearance &lt; 30 mL/min screen 6 . Systolic blood pressure ( SBP ) &lt; 90 mmHg screen 7 . Body weight &lt; 40 kg screen 8 . Known concomitant lifethreatening disease life expectancy &lt; 12 month 9 . Any condition prevents compliance protocol adherence therapy 10 . Treatment endothelin receptor antagonist ( ERAs ) within 3 month prior Visit 2 , schedule receive compound , macitentan , trial 11 . Treatment intravenous subcutaneous prostacyclin prostacyclin analog within 3 month prior Visit 2 , schedule receive compound trial 12 . Treatment riociguat within 3 month prior Visit 2 , schedule receive riociguat trial 13 . Treatment strong cytochrome P450 ( CYP ) 3A4 inducer inhibitor within 4 week prior Visit 2 14 . Recently start ( &lt; 8 week prior Visit 2 ) plan cardiopulmonary rehabilitation program base exercise 15 . Females lactate pregnant ( positive Screening Baseline pregnancy test ) plan become pregnant study 16 . Known hypersensitivity macitentan excipients drug class 17 . Treatment another investigational drug within 3 month prior Visit 2 18 . Any known factor disease might interfere treatment compliance , study conduct interpretation result drug alcohol dependence psychiatric disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>PAH-SYMPACT</keyword>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>psychometric instrument</keyword>
</DOC>